ERBB2 and breast carcinoma: For instance, certain mutations in ErbB1 (EGFR) and the amplification/overexpression of ErbB2 provide important targets for interrogation in non-small cell lung cancer (NSCLC) and breast cancer, respectively [20,21,22].